AIDS vaccine developments

Sir — In assessing vaccine strategies for preventing AIDS, Stott et al. reported that macaques immunized with uninfected C8166 cells (a T-cell line of human origin) were protected against subsequent intravenous infection by simian immunodeficiency virus (SIV), which induces an AIDS-like disease in macaques. Further investigation of the humoral response of vaccinated monkeys with SIV-infected and inactivated cells or with purified inactivated virus revealed that all animals have antibodies directed against cellular components, the strongest humoral immune response to both SIV and C8166 antigens. They also detected high ELISA titres against fresh human PBLs, whereas these animals raised weak antibody responses against rhesus macaque PBLs.

Eighteen weeks after the first challenge experiments, the protected animals of the high-dose vaccinated group were reboostered with the same vaccine preparation and challenged intravenously 2 weeks later with 10 AID50 of an homologous SIVMAC251 strain, produced by co-cultivating spleen cells of an infected monkey with fresh macaque PBLs: this virus has therefore never been exposed to a human cell. All monkeys developed clinical and biological evidence of infection (virus isolation by coculture, PCR, anamnestic response) 15 days after the second challenge experiment.

Controversial results from vaccine experiments highlight the difficulty in interpreting such experiments: cautious conclusions should include detailed discussions about controls. Our experiments do not exclude the possibility of antibody crossreactivity between cellular and lentivirus components, which Maddox suggests could contribute to the understanding of AIDS pathogenesis. Nevertheless, our results show that protection of macaques cannot be related to an immune crossreactivity between cellular components and SIV antigens.

Rather, we suggest that the strong anti-human cell immunity developed by our vaccinated macaques efficiently participates in protection (as previously suggested) through cellular antigens on the envelope of the human PBL-grown viruses used for the first challenge. The results we report here demonstrate the absolute necessity of designing vaccine experiments where viruses used for challenge infection are grown in PBL compatible with the host species. In addition, an alternative strategy to the investigation of the anti-lentiviral specific immune responses can be provided by highly purified antigens whatever their origins: inactivated viruses, recombinant or synthetic subunits.

Moreover, protection of these macaques against an homologous SIV challenge correlates with the ELISA titres against C8166 cells. Both vaccine preparations and the challenge virus stock were obtained from the same culture system: SIV-infected C8166 human cells.

As part of the European Communities’ AIDS Concerted Action programme, we immunized rhesus macaques with the same column-purified vaccine preparation (formalin-inactivated SIVMAC strain 251, 32H isolate, grown on human C8166 cells, provided by M. Cranage and P. Greenaway) in alum adjuvant. Two groups of animals received either 2 or 0.4 mg immunogen (days 0, 30, 60 and 135) and were challenged, 2 weeks after the final boost, with 10 AID50 (animal infectious dose 50%) of an heterologous SIVSM virus stock (provided by P. Putkonen) produced on fresh human peripheral blood lymphocytes (PBL) in 24. All four macaques in the high-dose immunized group, and two of three animals in the low-dose group, were protected more than 4 months after intravenous challenge.

We analysed the antibody responses of these monkeys. All animals exhibited high ELISA titres to uninfected C8166 cells as well as lentiviral-specific antigens. The high-dose vaccinated animals developed the highest humoral response to lentiviral and cellular antigens (see table). Surprisingly, ELISA titres were 10 times lower in the low-dose vaccinated group except for the unprotected monkey (No. 8,758), which developed

| ELISA TITRES AGAINST SIV AND CELLULAR ANTIGENS AT THE DAY OF CHALLENGE |
|-----------------|-----------------|-----------------|-----------------|
| Antigens detected | 2 mg vaccinated | 0.4 mg vaccinated | Control |
| SIV             | 5               | 5               | 4               | 5               |
| C8166 cells     | 4               | 4               | 4               | 5               |
| Human PBL       | 3               | 3               | 3               | 3               |
| Rhesus PBL      | 1               | 2               | 1               | 1               |

Neg, negative result. Regarding the high sequence homology of HIV-2 and SIV, the specific anti-SIV serum reactivity was determined using an HIV-2 antigen detection assay. We used the ELAVIA II kit (Diagnostics Pasteur) using as second antibody a peroxidase-labelled anti-monkey immunoglobulin G. Titres were determined as the last serum dilution, giving a significant positive optical density (OD) at 490 nm when compared to standards of 100 immune sera at the same serum dilution (cut off = OD average of immune sera + 2.26 s.d.). ND, not determined. ELISA titres expressed as log10.

Sir — Several groups have independently demonstrated that macaques may be protected from infection with simian immunodeficiency virus (SIV) by immunization with inactivated vaccines, based on either whole inactivated SIV or fixed SIV-infected cells, raising expectations that the development of a vaccine for the protection from human immunodeficiency virus (HIV) infection in man may be successful. It has become apparent that non-virus-specific cellular antigens present in SIV vaccine preparations used in those experiments may have played a role in the protection observed. The SIV virus stock used for challenge of vaccinated monkeys had been prepared from SIV-infected human T-cell lines, the same or similar to those used for production of the vaccine preparation itself.

We have carried out a vaccination challenge experiment in the same SIV-macaque model as part of the European Communities’ Concerted Action program. Our results indicate that at least part of the protection induced by inactivated SIV preparations is not due to immunization with non-virus-specific human T-cell antigens. To this end we have compared the efficacy of two SIV whole virus vaccine preparations, administered to two groups of seven and eight rhesus monkeys (Macaca mulatta), respectively. The first vaccine was an inactivated whole SIV preparation adjuvanted with muramyldipeptide (MDP) previously demonstrated to elicit protection; the second was an SIV-ismc preparation containing both the Gag and Env proteins of SIV. These vaccines had been prepared from the SIVMAC strain 251 (32H), propagated on the human T-cell line C8166 as described by Stott et al.3. Inactivated measles virus adjuvanted with MDP (MV- MDP) and an MV-ismc preparation served as controls, each of which were inoculated into two separate groups of four rhesus monkeys. Two weeks after the fourth intramuscular
PROTECTION INDUCED BY SIV VACCINES IN RHESUS MACAQUES

<table>
<thead>
<tr>
<th>Type of vaccine</th>
<th>Type of i.v. SIV challenge (10 MD₉₀)</th>
<th>Monkeys protected from viraemia/mice/day</th>
<th>Serum antibody titres measured in ELISA (log₁₀ M.I.D₉₀ ± s.d.) at day of challenge</th>
<th>Antigen</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIV-MDP</td>
<td>cell-free</td>
<td>4/4</td>
<td>SIV-env  2.4±0.4  C8166  2.0±0.2  RhPBCMC  1.9±0.1</td>
<td></td>
</tr>
<tr>
<td>SIV-iscom₁</td>
<td>cell-free</td>
<td>3/3</td>
<td>≤0.8  2.1±0.1  1.8±0.2</td>
<td></td>
</tr>
<tr>
<td>MV-MDP</td>
<td>cell-free</td>
<td>0/2</td>
<td>≤0.8  1.9±0.1  1.9±0.2</td>
<td></td>
</tr>
<tr>
<td>MV-iscom₁</td>
<td>cell-free</td>
<td>0/2</td>
<td>≤0.8  1.5±0.3  1.5±0.3</td>
<td></td>
</tr>
<tr>
<td>SIV-MDP</td>
<td>infected PBMC</td>
<td>2/4</td>
<td>3.3±0.4  2.1±0.1  1.9±0.1</td>
<td></td>
</tr>
<tr>
<td>SIV-iscom₁</td>
<td>infected PBMC</td>
<td>2/4</td>
<td>3.6±0.3  2.8±0.2  2.7±0.2</td>
<td></td>
</tr>
<tr>
<td>MV-MDP</td>
<td>infected PBMC</td>
<td>0/2</td>
<td>≤0.8  ≤1.5  1.9±0.3</td>
<td></td>
</tr>
<tr>
<td>MV-iscom₁</td>
<td>infected PBMC</td>
<td>0/2</td>
<td>≤0.8  ≤1.5  2.1±0.1</td>
<td></td>
</tr>
</tbody>
</table>

Viraemia was demonstrated by co-cultivation of PBMC with C8166 cells and subsequent demonstration of SIV antigen in the medium of P27-antigen capture assay. Results were confirmed by showing serum antibody induction (SIV-vaccinated monkeys) or booster fraction, in an SIV env-specific ELISA and Western blot assay.

1. SIV-Env: inhibition of reactivity of labelled SIV-neutralizing mouse monoclonal antibody (K5) by serial dilutions of monkey sera. K5 kindly provided by Dr K. Kent (through RC-ADP).
2. One animal not included (died during recovery at day of challenge).
3. C8166/RhPBCMC, reactivity of serial dilutions of serum monkey sera with solubilized membrane protein fraction (about 10 μg ml⁻¹) of respective cells attached to ConA-coated wells.

For vaccination all the monkeys were challenged intravenously with either 10 monkey infectious doses (MD₉₀) SIVMAC251 (32H) propagated in C8166 cells (group A), or with SIV-infected peripheral blood mononuclear cells (PBMC) obtained from an SIV-infected rhesus macaque (1×C) (group B). These PBMC had been prepared from heparinized blood of the monkey, 11 months after experimental infection with the same cell-free challenge stock of SIVMAC-251 (32H), frozen in 5×10⁶ cell aliquots and subsequently titrated in vivo in rhesus macaques. The equivalent of 10 MD₉₀ of these cells was used as challenge dose for group B.

The results are shown in the table. All the monkeys of group A vaccinated with SIV-MDP or SIV-iscom were protected from developing SIV viraemia for the 1-week observation period after intravenous cell-free SIVMAC-251 (32H) challenge, whereas all the MV-MDP and MV-iscom vaccinated monkeys developed SIV viraemia within 4 weeks after receiving the same cell-free challenge. Also all the MV-MDP and MV-iscom vaccinated monkeys of group B developed SIV viraemia within 2 weeks after intravenous challenge with SIV-infected PBMC. Two out of four SIV-MDP vaccinated monkeys and two out of four SIV-iscom vaccinated monkeys of group B were protected from SIV viraemia for the 9-week observation period after intravenous challenge with the SIV-infected PBMC.

These data were confirmed by demonstrating that all the monkeys that became SIV-viraemic also showed booster responses in their serum antibody titres measured in an SIV env-specific enzyme-linked immunosorbent assay (data not shown). At the day of all, SIV-vaccinated animals had developed serum antibody titres in this assay. In addition, antibodies directed against C8166 cells and rhesus PBMC present at that day were measured (see table). The protection found in group B among SIV-vaccinated monkeys did not correlate with the levels of serum antibody titres to C8166 cells or PBMC in these animals.

This is the first demonstration in the SIV-macaque model that vaccination can protect against challenge with cell-associated SIV, and is the first report that vaccinated, previously unchallenged non-human primates can be protected from infected PBMC from another infected animal. As the SIV challenge material used in group B was directly prepared from infected PBMC of the homologous species, the partial protection observed against this severe intravenous challenge should be attributed to immunization with SIV-specific antigens. Consequently the suggestion by Stott et al.¹, that virus- as well as cell-specific components can still be involved in protection after vaccination with inactivated SIV preparations, is strongly supported by our observations.

ALBERT OSTERHAUS
PETRA DE VRIES
National Institute of Public Health and Environmental Protection,
PO Box 1, 3720 BA Bilthoven,
The Netherlands

JONATHAN HEENEY
ITRI-NTO,
PO Box 5815,
2280 HV Rijswijk,
The Netherlands


SIR — Stott et al.¹ have presented evidence that the protection elicited with an SIV vaccine² containing fixed SIV-infected cells of human origin (C8166) may, at least in part, be mediated by anti-cell responses resulting from xenoinoculation. This surprising observation raises important questions about the nature of the protective responses elicited by other SIV vaccines.

As part of an AIDS vaccine development project, within the MRC AIDS Directed Programme and the European Communities' Concerted Action programme, we have immunized 10 rhesus macaques with a partially purified, inactivated virus vaccine based on the 32H isolate of SIVMAC strain 251 grown in C8166 cells (manuscript in preparation). Four animals (group A) each received four 500-μg doses of vaccine given in the Syntex adjuvant formulation 1 (saf-1). Another two groups of three animals each received the same vaccine given in alum, either as four 500-μg doses (group B) or as four 100-μg doses (group C). All animals were challenged intravenously 2 weeks after the final vaccine boost with 10 median monkey infectious doses (MD₉₀) of cell-free virus. Group A were challenged with SIVMAC-B670, a related but antigenically distinct strain of SIV, grown on human peripheral blood mononuclear cells (PBMC)³. Animals in groups B and C were challenged with homologous virus, that is the 32H isolate of SIVMAC-251 grown on C8166 cells.

Although unvaccinated control animals all became infected, all of the vaccinated animals were protected from infection as determined by the inability to recover virus from PBMC, inability to detect proviral DNA in PBMC and lack of an anamnestic antibody response. Animals were subsequently boosted further with vaccine, formulated as previously, at 16 months (group A) and 6.5 months (groups B and C) after initial challenge. At 2 weeks after the additional boost, all 10 animals plus 4 unvaccinated controls were challenged with 10 MD₉₀ of cell-free SIVMAC-251 grown in monkey PBMC. Virus was recovered from all of these animals as early as 2 weeks after challenge. Thus no protection from challenge was elicited despite the fact that the additional vaccination boosted the SIV-specific antibody response. In this experiment we have not